臨床泌尿器科65巻5号

2011年04月発行

綜説

ホルモン感受性を考慮した，去勢抵抗性前立腺癌（CRPC）の治療戦略

著者： 鈴木啓悦¹ 遠藤匠¹ 高野慎¹ 矢野仁¹ 直井牧人¹ 西見大輔¹ 神谷直人¹ 髙波眞佐治¹

所属機関： ¹東邦大学医療センター佐倉病院泌尿器科

ページ範囲：P.255 - P.266

文献概要

要旨　外科的精巣摘除術のみであったホルモン療法も，徐放性LH-RHアゴニストや非ステロイド性アンチアンドロゲン剤の開発などが進み，さまざまな治療様式が揃ってきた。以前はホルモン療法が，外科的去勢のみであったので，一度再燃するとそれは臨床的に再燃癌を意味していた。ところが，上述したように，ホルモン療法が多様化したこともあり，再燃癌の定義自体困難になってきた。このような背景の中，去勢抵抗性前立腺癌（castration-resistant prostate cancer：CRPC）という用語が広く用いられるようになってきた。本稿では，ホルモン感受性を意識した，CRPC治療戦略について概説する。

参考文献

1）Scher HI, Halabi S, Tannock I, et al：Design and endpoints of clinical trials for patients with progressive prostate cancer and castration levels of testosterone：recommendations of the prostate cancer clinical trials working group. J Clin Oncol 26：1148-1159, 2008

2）Saad F, Gleason DM, Murray R, et al：A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94：1458-1468, 2002

3）Tannock IF, de Wit R, Berry WR, et al：Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351：1502-1512 2004

4）Petrylak DP, Tangen CM, Hussain MH, et al：Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351：1513-1520, 2004

5）Scher HI, Steineck G and Kelly WK：Hormone-refractory（D3）prostate cancer：refining the concept. Urology 46：142-148, 1995

6）鈴木啓悦：アンチアンドロゲン除去症候群とアンドロゲンレセプター．日本臨牀増刊 58（前立腺癌の診断と治療―最新の研究動向）：434-436，2000

7）鈴木啓悦：アンチアンドロゲン交替療法の理論と実際．Urology View 4：24-28，2006

8）鈴木啓悦：再燃前立腺癌の治療．排尿障害プラクティス 17：59-66，2009

9）鈴木啓悦，市川智彦，三木恒治：進行前立腺癌の治療Update―抗（アンチ）アンドロゲン交替療法．Urology View 7：45-51，2009

10）Kojima S, Suzuki H, Akakura K, et al：Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol 171：679-683, 2004

11）Suzuki H, Okihara K, Miyake H, et al：Alternative non-steroidal antiandrogen therapy for advanced prostate cancer that has relapsed after initial maximum androgen blockade. J Urol 180：921-927, 2008

12）鈴木啓悦：前立腺癌のホルモン依存性―依存性喪失（再燃）機構を含めて．医学のあゆみ 213：527-532，2005

13）Suzuki H, Ueda T, Ichikawa T, et al：Androgen receptor involvement in the progression of prostate cancer. Endocr Relat Cancer 10：209-216, 2003

14）Fujii Y, Kawakami S, Masuda H, et al：Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy. BJU Int 97：1184-1189, 2006

15）Komiya A, Shimbo M, Suzuki H, et al：Oral low-dose dexamethasone for androgen-independent prostate cancer patients. Oncol Lett 1：73-79, 2010

16）Akakura K, suzuki H, Komiya A, et al：Possible mechanism of dexamethasone therapy for prostate cancer：suppression of circulating levels of interleukin-6. Prostate 56：106-109, 2003

17）Pienta KJ, Fisher EI, Eisenberger MA, et al：A phase Ⅱ trial of estramustine and etoposide in hormone refractory prostate cancer：a Southwest Oncology Group trial（SWOG9407）. Prostate 46：257-261, 2001

18）Dimopoulos MA, Panopoulos C, Bamia C, et al：Oral estramustine and oral etoposide for hormone-refractory prostate cancer. Urology 50：754-758, 1997

19）小宮　顕，鈴木啓悦，市川智彦：ホルモン不応前立腺癌の化学治療．Modern Physician 26：961-966，2006

20）Naito S, Tsukamoto T, Koga H, et al：Docetaxel plus prednisone for the treatment of metastatic hormone-refractory prostate cancer：a multicenter phase Ⅱ trial in Japan. Jpn J Clin Oncol 38：365-372, 2008

21）Berthold DR, Pond GR, de Wit R, et al：Survival and PSA response of patients in the TAX327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann of Oncol 19：1749-53, 2008

22）Beer TM, Ryan CW, Venner PM, et al：Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer. Cancer 112：326-330, 2008

23）Eymard JC, Oudard S, Gravis G, et al：Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer：a retrospective multucentre study. BJU Int 106：974-978, 2010

24）鈴木啓悦：前立腺癌．臨泌 63：327-333，2009

25）Armstrong AJ, Tannock IF, de Wit R, et al：The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer 26：517-525, 2010

26）Smith MR, McGovern FJ, Zietman AL, et al：Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345：948-955, 2001

27）Vordos D, Paule B, Vacherot F, et al：Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer. BJU Int 94：524-527, 2004

28）Gnant M, Mlineritsch B, Schippinger W, et al：Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360：679-691, 2009

29）Suzuki H, Kamiya N, Imamoto T, et al：Current topics and perspectives relating to hormone therapy for prostate cancer. Int J Clin Oncol 13：401-410, 2008

30）Mostaghel EA and Nelson PS：Intracrine androgen metabolism in prostate cancer progression：mechanisms of castration resistance and therapeutic implications. Best Practice & Research Clinical Endocrinology & Metabolism, 2008

31）Attard G, Reid AH, A'Hern R, et al：Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 27：3742-3748, 2009

32）Vasaitis TS, Bruno RD, Njar VC, et al：CYP17 Inhibitors for Prostate Cancer Therapy. J Steroid Biochem Mal Biol 2010（Epub ahead）

33）Scher HI, Beer TM, Higano CS, et al：Antitumour activity of MDV3100 in castration-resistant prostate cancer：a phase 1-2 study. Lancet 375：1437-1446, 2010

34）Agarwal N, Sonpavde G and Sartor O：Cabazitaxel for the treatment of castration-resistant prostate cancer. Future Oncol 7：15-24, 2011